English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Towards motion-free diagnostic coronary MRA, lengthy (10-15 min) sequences are required. Conventional GBCAs are unable to sustain steady-state intravascular concentrations long enough to maintain low enough T1 signal for good signal/contrast to noise levels[1]. Arterial and venous mixing of contrast takes time that cannot be used for scanning using our free-breathing self-navigated motion-corrected MRA sequence[2,3]. Gadofosveset has a high intravascular residence time and high relaxivity compared to other GBCAs; therefore, we study various injection parameters to accomplish a low T1 time for the longest period of time, as well as a quick equilibrium time with this agent using a dual bolus/slow infusion injection technique.

Optimization of gadofosveset intravenous injection scheme for coronary MRA: the pharmacokinetics approach